ArticleiScience2026
Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemia.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy offers promising opportunities to improve immune-mediated control of chronic myeloid leukemia (CML), but its success depends on identifying antigens uniquely associated with CML. Protein kinases regulate signaling and protein turnover, influencing which peptides are presented on HLA molecules. Although earlier studies suggested that kinase inhibition can alter immune recognition of cancer cells, the underlying mechanisms remain unclear. In this study, we investigated whether targeting key kinases could reshape the CML immunopeptidome. The pharmacological inhibition of SFK, JNK, and BCR-ABL caused broad remodeling of antigen presentation, affecting the display of 4,000 HLA-I ligands. By integrating immunopeptidomics, phospho-immunopeptidomics, and proteomics, we identified three complementary mechanisms regulating antigen display. Comparing benign hematologic tissues with CML samples revealed about 90 CML-specific peptides that became more prominent after SFK or JNK inhibition. Overall, this work provides a quantitative, multi-omic framework to rationally combine kinase inhibitors with immunotherapy to boost antigen visibility and antileukemic immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.